Preclinical feature articles

61. Increased Adoption Of iPSC-Derived Human Cells For Use In Drug Discovery And Toxicity Testing 10/1/2012

    Traditionally, discovering a pharmacological therapy for a disease involves first investigating the underlying biological processes of that condition and then identifying drug candidates that interfere with those processes.  From here, the most promising compounds are advanced to pre-clinical and clinical development. The goal of this “bench to bedside” approach is to translate bench research to point-of-care patient outcomes as quickly and safely as possible. With dwindling drug pipelines, pharmaceutical companies need new approaches that can re-energize their discovery efforts. By Chris Parker, Vice President and Chief Commercial Officer, Cellular Dynamics International

62. March Madness - Coast To Coast To Attend SOT And DCAT 3/20/2012
    I recently had the opportunity to attend two different events — the Society of Toxicology ToxExpo (SOT) and the Drug, Chemical, and Associated Technologies Week (DCAT). By Rob Wright, Chief Editor, Life Science Leader magazine